Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on Wednesday, August 14, 2024, at 3:00pm Eastern Time.
This presentation marks an important opportunity for Neuronetics to showcase its progress and future plans to investors and industry professionals. The event will be accessible via a live audio webcast on the investor relations page of Neuronetics' website at ir.neuronetics.com, allowing interested parties to tune in remotely.
As a company focused on improving the quality of life for patients with neurohealth disorders, Neuronetics' participation in this conference could provide valuable insights into their latest developments and market strategies.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica specializzata nei disturbi neuro-salutari, ha annunciato la sua partecipazione alla 44a Conferenza Annuale sulla Crescita di Canaccord Genuity. Il team di gestione dell'azienda presenterà mercoledì 14 agosto 2024, alle 15:00 ora orientale.
Questa presentazione rappresenta un'importante opportunità per Neuronetics di mostrare i suoi progressi e i piani futuri agli investitori e ai professionisti del settore. L'evento sarà accessibile tramite un webcast audio dal vivo sulla pagina delle relazioni con gli investitori del sito web di Neuronetics all'indirizzo ir.neuronetics.com, consentendo a chi è interessato di seguire l'evento da remoto.
Essendo un'azienda orientata al miglioramento della qualità della vita dei pazienti con disturbi neuro-salutari, la partecipazione di Neuronetics a questa conferenza potrebbe fornire preziose intuizioni sui loro ultimi sviluppi e strategie di mercato.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en trastornos neuro-saludables, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo de gestión de la empresa presentará el miércoles 14 de agosto de 2024, a las 3:00 p.m. hora del este.
Esta presentación representa una oportunidad importante para que Neuronetics muestre su progreso y planes futuros a los inversores y profesionales de la industria. El evento será accesible a través de un webcast de audio en vivo en la página de relaciones con los inversores del sitio web de Neuronetics en ir.neuronetics.com, permitiendo a las partes interesadas sintonizar de forma remota.
Como una empresa enfocada en mejorar la calidad de vida de los pacientes con trastornos neuro-saludables, la participación de Neuronetics en esta conferencia podría proporcionar valiosas ideas sobre sus últimos desarrollos y estrategias de mercado.
Neuronetics (NASDAQ: STIM), 신경 건강 장애를 전문으로 하는 의료 기술 회사가 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참가한다고 발표했습니다. 회사 관리 팀은 2024년 8월 14일 수요일 오후 3시 동부 시간에 발표할 예정입니다.
이번 발표는 Neuronetics가 투자자와 업계 전문가들에게 진전 및 향후 계획을 보여줄 중요한 기회를 의미합니다. 이 행사는 Neuronetics 웹사이트의 투자자 관계 페이지인 ir.neuronetics.com에서 실시간 오디오 웹캐스트를 통해 접속 가능하며, 관심 있는 사람들이 원격으로 참여할 수 있습니다.
신경 건강 장애 환자의 생활 질 향상에 집중하고 있는 회사로서, Neuronetics의 이번 컨퍼런스 참가가 최신 개발 및 시장 전략에 대한 귀중한 통찰력을 제공할 수 있습니다.
Neuronetics (NASDAQ: STIM), une entreprise de technologie médicale spécialisée dans les troubles de la neuro-santé, a annoncé sa participation à la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity. L'équipe de direction de l'entreprise est prévue pour présenter le mercredi 14 août 2024 à 15h00, heure de l'Est.
Cette présentation constitue une occasion importante pour Neuronetics de montrer ses progrès et ses projets futurs aux investisseurs et aux professionnels de l'industrie. L'événement sera accessible via un webinaire audio en direct sur la page des relations avec les investisseurs du site Web de Neuronetics à l'adresse ir.neuronetics.com, permettant ainsi aux parties intéressées de se connecter à distance.
En tant qu'entreprise axée sur l'amélioration de la qualité de vie des patients atteints de troubles de la neuro-santé, la participation de Neuronetics à cette conférence pourrait fournir des perspectives précieuses sur ses développements récents et ses stratégies de marché.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf neurogesundheitliche Störungen spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Das Management-Team des Unternehmens wird am Mittwoch, den 14. August 2024, um 15:00 Uhr Eastern Time präsentieren.
Diese Präsentation stellt eine wichtige Gelegenheit für Neuronetics dar, seinen Fortschritt und zukünftige Pläne Investoren und Branchenfachleuten vorzustellen. Die Veranstaltung wird über ein live Audio-Webcast auf der Investor-Relations-Seite der Neuronetics-Website unter ir.neuronetics.com zugänglich sein, sodass interessierte Parteien remote teilnehmen können.
Als ein Unternehmen, das sich auf die Verbesserung der Lebensqualität von Patienten mit neurogesundheitlichen Störungen konzentriert, könnte die Teilnahme von Neuronetics an dieser Konferenz wertvolle Einblicke in ihre neuesten Entwicklungen und Marktstrategien bieten.
- None.
- None.
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When is Neuronetics (STIM) presenting at the Canaccord Genuity 44th Annual Growth Conference?
How can I access Neuronetics' (STIM) presentation at the Canaccord Genuity conference?
What is the focus of Neuronetics (STIM) as a medical technology company?
Where is Neuronetics (STIM) headquartered?
